by NSC Cardiology Team | Feb 6, 2021
A new class of drugs called PCSK9 inhibitors have recently come to market. These are monoclonal antibodies that improve the liver’s ability to get rid of excess cholesterol by increasing LDL receptors. By now we all recognize that there are two forms of cholesterol-...
Recent Comments